BIOBETTER DATABASE

CDC-Enhanced Antibodies: Unlocking the Power of Complement-Dependent Cytotoxicity

Cdc-enhanced antibodies represent a breakthrough class of therapeutic biologics designed to harness the full potential of the immune system’s complement cascade. By precisely engineering the Fc region, Creative Biolabs introduces a new era of antibody therapies that are optimized for enhanced complement-dependent cytotoxicity (CDC).

Key Features of Creative Biolabs' CDC-Enhanced Antibodies:

Fc Region Optimization: Targeted mutations to the Fc region of antibodies improve C1q binding, amplifying complement activation.

Enhanced Antitumor Potency: By boosting CDC activity, these antibodies show superior tumor cell-killing capabilities.

Reduced Immune Evasion: Engineered antibodies are less susceptible to immune escape mechanisms, enhancing long-term therapeutic outcomes.

Customizable Solutions: We work closely with our clients to develop and fine-tune CDC-enhanced antibodies for specific therapeutic applications.

Explore Our CDC-Enhanced Antibody Portfolio

Browse our comprehensive range of CDC-enhanced antibody products designed for a variety of disease targets. If you have a specific therapeutic need or require a custom solution, our team of experts is ready to collaborate with you to create the ideal CDC-enhanced antibody for your research or other program.

• TargetSelect Target4-1BB5ACAbetaACVR2BACVRL1Adenocarcinoma antigenAFPAOC3APCSB-lymphoma cellB. anthracis PAB. anthrasis PABAFFBLySBSGC-X-C motif chemokine 10C. difficile toxin BC5CA 125CA9Carcinoma associated antigen CTAA16 (complex of cytokeratin polypeptides 35-40kDa)cardiac myosinCCL11CCL2CCR2CCR4CD11aCD11ACD140aCD15CD15/FUT4CD18CD19CD2CD20CD200CD22CD23CD248CD25CD252CD27CD274CD276CD28CD3CD3 epsilonCD3 receptorCD30CD33CD37CD38CD3ECD4CD40CD40 ligandCD40LGCD44CD5CD51CD51+CD61CD56CD6CD70CD73CD79BCD80CEACEACAM5CEACAM8CFDCGRPClostridium difficile enterotoxin BCMVComplement component 5CRCPCSF1CSF1RCSF2CTGFCTLA-4CTLA4CXCR4DLL4DNA/histone H1 complexDR5E. coli Shiga-like toxin II BE. coli Stx1BE. coli Stx2AEbolavirus glycoproteinEBOVEGFL7EGFREGFR/HER1endotoxinENGEPCAMEpCAMEPHA3ERBB2ERBB2/CD340ERBB3F3FAPFCGRTFGF23fibronectin extra domain-BFLT1folate receptor 1FOLH1Frizzled Receptorganglioside GD3GD2GD3 GangliosideGPC3GPNMBHAHBVHBV Surface AntigenHCMVheat shock protein 90 homolog [Candida albicans]HER2HGFHIV-1HLA DR betaHSP60IAV HAIBV HAICOSLIFN alphaIFNA1IFNGIFNγIgEIgE FcIGF1 and IGF2IGF1 ReceptorIGF1RIGF2IGHEIL-13IL-17αIL-1βIL-23 p19IL-2RIL-5IL-5RIL-6IL-6RIL1 betaIL12+IL23IL13IL17IL17AIL17RAIL20IL22IL23IL23AIL31IL31RAIL4IL5IL5RAIL6IL6RIL9Influenza A hemagglutininIntegrin alpha 4 beta 7Integrin alpha 5 beta 1interferon α/β receptorITGA2ITGA4ITGA4 and ITGB7ITGAVITGB2KDRKIRD2 subgroupKLRC1LINGO1LOXL2LTAMAGMesothelinMETMIFMMP9MS4A1MSLNMST1RMSTNMUC1MUC1 (Mucin1)MUC16NCA-90NCAM1NGCGM3NGFNogo-ANOTCH1NOTCH2NRP1P. aeruginosa Serotype IATS O11PAPCSK9PD-1PD-L1PDCD1PDGF-R alphaPDGFRAPhosphatidylserinePMSAPVRL4Rabies virusrespiratory syncytial virusRGMARHDRSPO3RSVRSV FRTN4S. aureusS. epidermidis LTAS1PSclerostinSDC1selectin PSELLSELPSLAMF7SLC34A2SOSTTAG72TCRTenascin C/TNCTFPITGF beta 2TGFB1TNFTNF-alphaTNFRSF10ATNFRSF10BTNFRSF4TNFRSF8TNFRSF9TNFSF11TNFSF12TNFαtoxin A [C. difficile]TSLPtumour associated glycoprotein 72VEGFVEGF Receptor 2VEGF-AVEGFAVEGFR2VIMVon Willebrand Factorα4β7 integrinαVβ3 integrin